SEC 13F Intelligence

Managers / Q3 2023 · view latest →

Gates Foundation

CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100

Reported Value
$84M
Q3 2023
Positions
9
Filings on Record
19
2019–present window
Filed
Nov 13, 2023
original filing

Summary

Gates Foundation reported $84M in U.S.-listed holdings across 9 positions for Q3 2023.

The portfolio is heavily concentrated: IMCR alone accounts for 35.7% of reported value.

The book was largely unchanged from Q2 2023.

Portfolio Metrics

Turnover
+0.1%
vs prior filed quarter
Largest Position
+35.7%
Immuncore

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $438MQ4 ’20Q1 ’21: $656MQ2 ’21: $692MQ2 ’21Q3 ’21: $342MQ4 ’21: $330MQ4 ’21Q1 ’22: $186MQ2 ’22: $130MQ2 ’22Q3 ’22: $127MQ4 ’22: $130MQ4 ’22Q1 ’23: $113MQ2 ’23: $126MQ2 ’23Q3 ’23: $84MQ4 ’23: $90MQ4 ’23Q1 ’24: $84MQ2 ’24: $60MQ2 ’24Q3 ’24: $44Mfilingsflow.com

Portfolio Composition

By security type
ADR: 63.5%Common Stock: 19.1%Other: 17.3%
  • ADR · 63.5% · $53M
  • Common Stock · 19.1% · $16M
  • Other · 17.3% · $15M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ATRECA INCHELD19.2K912.6K$675,892$237,287
VIRVIR BIOTECHNOLOGY INCHELD+01.56M$24M$15M
CUREVAC N VHELD+01.63M$6M$11M
IMCRIMMUNCORE HLDGS PLCHELD+0576.9K$5M$30M
LUMIRADX LTDHELD+014.29M$3M$3M
EXSCIENTIAHELD+01.59M$2M$7M
BFLYBUTTERFLY NETWORK INCHELD+01.01M$1M$1M
AMYRIS INCHELD+0292.4K$283,626$17,544

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

9 positions
#IssuerClass% PortfolioValueShares
1IMCRIMMUNCORE HLDGS PLChistory →ADS35.70%$30M576.9K
2BNTXBIONTECH SEhistory →SPONSORED ADS19.26%$16M148.7K
3VIRVIR BIOTECHNOLOGY INChistory →COM17.42%$15M1.56M
4CUREVAC N VCOM13.24%$11M1.63M
5EXSCIENTIAADS8.57%$7M1.59M
6LUMIRADX LTDSHS4.09%$3M14.29M
7BFLYBUTTERFLY NETWORK INChistory →CL A COM1.42%$1M1.01M
8ATRECA INCCL A COM0.28%$237,287912.6K
9AMYRIS INCCOM NEW0.02%$17,544292.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$44M5Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$60M6Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$84M8May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$90M8Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$84M9Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$126M9Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$113M9May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$130M9Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$127M10Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$130M9Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$186M11May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$330M11Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M10Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$692M8Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$656M7May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$438M5Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.